To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min National celebrity Bill Nye ...

Home-based high-intensity aerobic training was associated with greater improvement in cerebellar ataxia symptoms, fitness, and fatigue compared with guidelines-recommended balance training in a ...

It was 1987, I was 16 and I was working at the Denny’s on Burrard Street. My stepfather used to watch me head to work every day. One afternoon, he asked if I’d hurt my leg. I was limping, though I ...

The backpack, known as the Gyropack, uses gyroscopic technology similar to that used in space stations or large satellites to maintain orientation in space. An innovative backpack, incorporating ...

Please provide your email address to receive an email when new articles are posted on . Vatiquinone inhibits 15-Lipoxygenase, which regulates the pathways that Friedreich’s ataxia disrupts. PTC ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...

Spinocerebellar ataxia type 1 (SCA1) and Machado-Joseph disease (MJD/SCA3) are autosomal dominant neurodegenerative diseases caused by expansions of a CAG trinucleotide repeat in the SCA1 and MJD ...

The Gehr family has always had a love and a talent for the performing arts. “I really lived a pretty unaffected life until about third grade,” said 25-year-old Michael Gehr. As a kid, Michael was what ...

The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe are thoroughly working toward the development of new drug therapy options to treat this disease.

TORONTO, June 5, 2025 /CNW/ - Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with ...

Friedreich ataxia (FRDA) is the most common type of inherited ataxia. It is a neurodegenerative disorder characterized by progressive gait and limb ataxia, dysarthria, areflexia, and reduced ...